Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an intravenous solution for use in hospital settings. It is employed to prevent cerebral vasospasm that can follow a subarachnoid haemorrhage, helping to maintain adequate cerebral blood flow in affected patients.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine acts on the cerebrovascular system to reduce the risk of vessel narrowing after bleeding in the brain.

- Prevention of cerebral vasospasm following subarachnoid haemorrhage: helps maintain cerebral perfusion and reduces the incidence of delayed ischaemic neurological deficits. - Adjunct in neurocritical care: supports overall management of patients at risk of secondary cerebral ischaemia after traumatic brain injury. - Research settings involving cerebral blood flow modulation: used as a tool to study vascular responses in experimental protocols.

Nimodipine may cause a range of adverse reactions, most of which are related to its vasodilatory action and systemic exposure.

Common Side Effects: - Headache: mild to moderate, often transient. - Hypotension: reduction in systemic blood pressure, especially with rapid infusion. - Nausea or vomiting: gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension leading to syncope or organ hypoperfusion. - Cardiac arrhythmias, including bradycardia. - Hepatic dysfunction manifested by elevated transaminases. - Anaphylactic or severe allergic reactions requiring immediate medical attention.

Before initiating Nimodipine therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: observe for hypotension during and after infusion. - Hepatic function: avoid or adjust dose in patients with significant liver impairment. - Concomitant vasodilators: use caution when combined with other agents that lower blood pressure. - Infusion rate: administer slowly to minimise rapid drops in systemic pressure. - Known hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other calcium channel blockers: additive vasodilatory effect may cause profound hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma concentrations, raising toxicity risk. - Concurrent strong vasodilators (e.g., nitroglycerin): may precipitate severe blood pressure falls.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - Beta‑blockers: combined effect on heart rate and blood pressure requires observation. - Diuretics: may enhance orthostatic hypotension, necessitating dose adjustments.